Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
复制标题
DOI：
10.1001/jamapsychiatry.2013.678
复制
发表时间：
2013-05
期刊：
影响因子：
25.8
通讯作者：
Wetter, David W.
中科院分区：
文献类型：
--
作者：
Cinciripini, Paul M.;Robinson, Jason D.;Karam-Hage, Maher;Minnix, Jennifer A.;Lam, Cho;Versace, Francesco;Brown, Victoria L.;Engelmann, Jeffrey M.;Wetter, David W.
戒烟临床试验 评估安非他酮和伐尼克兰对戒烟和情绪功能的相对功效。安慰剂对照随机临床试验 大学医学中心 294 名想要戒烟的社区志愿者接受 12 周的 Varenicline、安非他酮 SR 或安慰剂加强化戒烟咨询（10 次约 240 分钟）。长期戒烟，每周测量抑郁、负面情绪和其他尼古丁戒断症状。在治疗结束时和戒烟后 3 个月的随访中发现，活性药物与安慰剂的戒烟情况存在显着差异。在 6 个月的随访中，只有伐尼克兰与安慰剂的比较仍然显着。与其他治疗方法相比，伐尼克兰还与抑郁症的普遍抑制和吸烟奖励的减少有关，而与安慰剂相比，这两种药物都可以提高注意力，减少渴望，减少负面情绪和悲伤，而对焦虑和愤怒几乎没有影响（增加或减少）。自我报告的神经精神不良事件发生率没有差异。相对于安慰剂，伐尼克兰对戒烟产生强大而有利的影响，并且可能对抑郁症状和其他情感措施产生有利（抑制作用），而对社区样本中的神经精神不良事件没有明显的不利影响
Smoking cessation clinical trial Assess the relative efficacy of bupropion and varenicline on smoking cessation and emotional functioning. Placebo controlled randomized clinical trial University Medical Center 294 community volunteers who wanted to quit smoking 12 weeks of Varenicline, Bupropion-SR, or Placebo plus intensive smoking cessation counseling (10 sessions ~240 minutes). Prolonged abstinence from smoking, and weekly measures of depression, negative affect and other symptoms of nicotine withdrawal Significant differences were found in abstinence at the end of treatment and through the 3-month post-quit follow-up favoring both active medications vs. placebo At the 6 month follow-up only the varenicline vs. placebo comparison remained significant. Varenicline was also associated with a generalized suppression of depression and reduced smoking reward compared to the other treatments, while both medications improved concentration, reduced craving, and decreased negative affect and sadness compared to placebo, while having little impact (increase or decrease) on anxiety and anger. No differences were noted in self-reported rates of neuropsychiatric adverse events. Varenicline exerts a robust and favorable impact on smoking cessation relative to placebo and may have a favorable (suppressive effect) on symptoms of depression and other affective measures with no clear unfavorable impact on neuropsychiatric adverse events in a community sample
登录
查看更多内容
影响因子：
1.4
作者：
Cahill, Kate;Stead, Lindsay F.;Polonio, Igor Bastos
通讯作者：
Polonio, Igor Bastos
影响因子：
5.3
作者：
Sheehan, DV;Lecrubier, Y;Dunbar, GC
通讯作者：
Dunbar, GC
DOI：
10.1093/ntr/ntr220
发表时间：
2012-03
期刊：
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
影响因子：
--
作者：
Rennard S;Hughes J;Cinciripini PM;Kralikova E;Raupach T;Arteaga C;St Aubin LB;Russ C;Flexible Quit Date Study Group
通讯作者：
Flexible Quit Date Study Group
影响因子：
3.1
作者：
FAGERSTROM, KO
通讯作者：
FAGERSTROM, KO
影响因子：
8
作者：
Law, KL;Stroud, LR;Lester, BM
通讯作者：
Lester, BM